Biology and therapy of fibromyalgia: Pain in fibromyalgia syndrome

Arthritis Research and Therapy

Volumn 8, Issue 3, 2006, Pages

  Staud, Roland ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CYTOKINE; DEXTROMETHORPHAN; KETAMINE; MUSCLE RELAXANT AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NARCOTIC AGENT; NEUROKININ 1 RECEPTOR; SUBSTANCE P;

BEHAVIOR THERAPY; BRAIN; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; COGNITIVE THERAPY; CYTOKINE PRODUCTION; DRUG RECEPTOR BINDING; FIBROMYALGIA; GLIA CELL; HUMAN; IRRITABLE COLON; LOW BACK PAIN; MIGRAINE; MORBIDITY; MUSCLE TISSUE; MYOFASCIAL PAIN; NERVE CELL PLASTICITY; NOCICEPTION; NONHUMAN; PATHOGENESIS; PHYSIOTHERAPY; POPULATION RESEARCH; REVIEW; SENSITIZATION; SLEEP DISORDER; SPINAL CORD; TEMPORAL SUMMATION; CLASSIFICATION; PAIN; PATHOPHYSIOLOGY;

FIBROMYALGIA; HUMANS; PAIN;

EID: 33745239716     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1950     Document Type: Review

References (75)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172.
2. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F: Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994, 37:1593-1601.
3. Bradley LA, Alarcon GS, Sotolongo A, Weigent DA, Alberts KR, Blalock JE, Kersh BC, Domino ML, De Waal D: Cerebrospinal fluid (CSF) levels of substance P (SP) are abnormal in patients with fibromyalgia (FM) regardless of traumatic or insidious pain onset. Arthritis Rheum 1998, 41:S256.
4. Vaeroy H, Helle R, Forre O, Kass E, Terenius L: Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988, 32:21-26.
5. Neeck G: Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients. Scand J Rheumatol 2000, 29:8-12.
6. Lautenschlager J, Bruckle W, Schnorrenberger CC, Muller W: Measuring pressure pain of tendons and muscles in healthy probands and patients with generalized tendomyopathy (fibromyalgia syndrome). Z Rheumatol 1988, 47:397-404.
7. Quimby LG, Block SR, Gratwick GM: Fibromyalgia: generalized pain intolerance and manifold symptom reporting. J Rheumatol 1988, 15:1264-1270.
8. Tunks E, Crook J, Norman G, Kalaher S: Tender points in fibromyalgia. Pain 1988, 34:11-19.
9. Mikkelsson M, Latikka P, Kautiainen H, Isomeri R, Isomaki H: Muscle and bone pressure pain threshold and pain tolerance in fibromyalgia patients and controls. Arch Phys Med Rehabil 1992, 73:814-818.
10. Kosek E, Ekholm J, Hansson P: Increased pressure pain sensibility in fibromyalgia patients is located deep to the skin but not restricted to muscle tissue. Pain 1995, 63:335-339.
11. Loeser JD: What is chronic pain? Theor Med 1991, 12:213-225.
12. Price DD: Psychological Mechanisms of Pain and Analgesia: Progress in Pain Research and Management. 15th edition. Seattle: IASP Press; 1999.
13. Rainville P, Bao QV, Chretien P: Pain-related emotions modulate experimental pain perception and autonomic responses. Pain 2005, 118:306-318.
14. Merskey H, Bogduk N: Classification of Chronic Pain: Description of Chronic Pain Syndromes and Definition of Pain Terms. 2nd edition. Seattle: IASP Press; 1994.
15. Crofford LJ, Young EA, Engleberg NC, Korszun A, Brucksch CB, McClure LA, Brown MB, Demitrack MA: Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun 2004, 18:314-325.
16. Crofford LJ: The hypothalamic-pituitary-adrenal axis in fibromyalgia: Where are we in 2001? J Musculoskelet Pain 2002, 10:215-220.
17. Bradley LA, Sotolongo A, Alberts KR, Alarcon GS, Mountz JM, Liu HG, Kersh BC, Domino ML, DeWaal D, Weigent DA, et al.: Abnormal regional cerebral blood flow in the caudate nucleus among fibromyalgia patients and non-patients is associated with insidious symptom onset. J Musculoskelet Pain 1999, 7:285-292.
18. Larson AA, Giovengo SL, Russell IJ, Michalek JE: Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000, 87:201-211.
19. Giovengo SL, Russell IJ, Larson AA: Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999, 26:1564-1569.
20. Simms RW: Fibromyalgia is not a muscle disorder. Am J Med Sci 1998, 315:346-350.
21. Sprott H, Bradley LA, Oh SJ, Wintersberger W, Alarcon GS, Mussell HG, Tseng A, Gay RE, Gay S: Immunohistochemical and molecular studies of serotonin, substance P, galanin, pituitary adenylyl cyclase-activating polypeptide, and secretoneurin in fibromyalgic muscle tissue. Arthritis Rheum 1998, 41:1689-1694.
22. Sprott H, Salemi S, Gay RE, Bradley LA, Alarcon GS, Oh SJ, Michel BA, Gay S: Increased DNA fragmentation and ultra-structural changes in fibromyalgic muscle fibres. Ann Rheum Dis 2004, 63:245-251.
23. Salemi S, Rethage J, Wollina U, Michel BA, Gay RE, Gay S, Sprott H: Detection of interleukin 1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol 2003, 30:146-150.
24. Graven-Nielsen T, Arendt-Nielsen L: Is there a relation between intramuscular hypoperfusion and chronic muscle pain? J Pain 2002, 3:261-263.
25. Elvin A, Siosteen AK, Nilsson A, Kosek E: Decreased muscle blood flow in fibromyalgia patients during standardised muscle exercise: A contrast media enhanced colour doppler study. Eur J Pain 2006, 10:137-144.
26. Staud R, Vierck CJ, Robinson ME, Price DD: Overall fibromyalgia pain is predicted by ratings of local pain and pain related negative affect: possible role of peripheral tissues. Rheumatology 2006, in press.
27. Wigers SH: Fibromyalgia outcome: the predictive values of symptom duration, physical activity, disability pension, and critical life events - a 4.5 year prospective study. J Psychosom Res 1996, 41:235-243.
28. Macfarlane GJ, Thomas E, Papageorgiou AC, Schollum J, Croft PR, Silman AJ: The natural history of chronic pain in the community: a better prognosis than in the clinic? J Rheumatol 1996, 23:1617-1620.
29. Winfield JB: FMS as functional somatic syndrome. Arthritis Rheum 2001, 44:751-753.
30. Hunt IM, Silman AJ, Benjamin S, McBeth J, Macfarlane GJ: The prevalence and associated features of chronic widespread pain in the community using the 'Manchester' definition of chronic widespread pain. Rheumatology 1999, 38:275-279.
31. Croft P, Rigby AS, Boswell R, Schollum J, Silman A: The prevalence of chronic widespread pain in the general population. J Rheumatol 1993, 20:710-713.
32. Benjamin S, Morris S, McBeth J, Macfarlane GJ, Silman AJ: The association between chronic widespread pain and mental disorder - A population-based study. Arthritis Rheum 2000, 43: 561-567.
33. Forseth KO, Forre O, Gran JT: A 5.5 year prospective study of self-reported musculoskeletal pain and of fibromyalgia in a female population: Significance and natural history. Clin Rheumatol 1999, 18:114-121.
34. McBeth J, Macfarlane GJ, Benjamin S, Silman AJ: Features of somatization predict the onset of chronic widespread pain: results of a large population-based study. Arthritis Rheum 2001, 44:940-946.
35. Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz DA, Auchenbach MB, Starck LO, Keck PE: Family study of fibromyalgia. Arthritis Rheum 2004, 60:944-952.
36. Thieme K, Turk DC, Flor H: Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med 2004, 66:837-844.
37. Raphael KG, Janal MN, Nayak S, Schwartz JE, Gallagher RM: Familial aggregation of depression in fibromyalgia: a community-based test of alternate hypotheses. Pain 2004, 110:449-460.
38. Woolf CJ: Windup and central sensitization are not equivalent. Pain 1996, 66:105-108.
39. Li J, Simone DA, Larson AA: Windup leads to characteristics of central sensitization. Pain 1999, 79:75-82.
40. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD: Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001, 91:165-175.
41. Dickenson AH, Sullivan AF: Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology 1987, 26:1235-1238.
42. Mendell LM, Wall PD: Responses of single dorsal cord cells to peripheral cutaneous unmyelinated fibres. Nature 1965, 206: 97-99.
43. Price DD, Mao J, Frenk H, Mayer DJ: The N-methyl-D-aspartate receptor antagonist dextromethorphan selectively reduces temporal summation of second pain in man. Pain 1994, 59: 165-174.
44. Staud R, Vierck CJ, Robinson ME, Price DD: Effects of the NDMA receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal controls. J Pain 2005, 6:323-332.
45. Vierck CJ, Cannon RL, Fry G, Maixner W, Whitsel BL: Characteristics of temporal summation of second pain sensations elicited by brief contact of glabrous skin by a preheated thermode. J Neurophysiol 1997, 78:992-1002.
46. Woolf CJ, Costigan M: Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci USA 1999, 96:7723-7730.
47. Staud R, Domingo M: Evidence for abnormal pain processing in fibromyalgia syndrome. Pain Med 2001, 2:208-215.
48. Staud R, Domingo M: New Insights into the pathogenesis of fibromyalgia syndrome. Med Aspects Hum Sex 2001, 1:51-57.
49. Vierck CJ, Staud R, Price DD, Cannon RL, Mauderli AP, Martin AD: The effect of maximal exercise on temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. J Pain 2001, 2:334-344.
50. Staud R: Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep 2002, 4:299-305.
51. Price DD, Staud R, Robinson ME, Mauderli AP, Cannon RL, Vierck CJ: Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain 2002, 99: 49-59.
52. King T, Gardell LR, Wang RZ, Vardanyan A, Ossipov MH, Malan TP, Vanderah TW, Hunt SP, Hruby VJ, Lai J, et al.: Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 2005, 116:276-288.
53. Staud R, Robinson ME, Vierck CJ, Cannon RL, Mauderli AP, Price DD: Ratings of experimental pain and pain-related negative affect predict clinical pain in patients with fibromyalgia syndrome. Pain 2003, 105:215-222.
54. Watkins LR, Milligan ED, Maier SF: Glial activation: a driving force for pathological pain. Trends Neurosci 2001, 24:450-455.
55. Wieseler-Frank J, Maier SF, Watkins LR: Glial activation and pathological pain. Neurochem Int 2004, 45:389-395.
56. Holguin A, O'Connor KA, Biedenkapp J, Campisi J, Wieseler-Frank J, Milligan ED, Hansen MK, Spataro L, Maksimova E, Bravmann C, et al.: HIV-1 gp120 stimulates proinflammatory cytokine-mediated pain facilitation via activation of nitric oxide synthase-1 (nNOS). Pain 2004, 110:517-530.
57. Wieseler-Frank J, Maier SF, Watkins LR: Central proinflammatory cytokines and pain enhancement. Neurosignals 2005, 14: 166-174.
58. Watkins LR, Maier SF: When good pain turns bad. Curr Directions Psych Sci 2003, 12:232-236.
59. Salter MW: Cellular signalling pathways of spinal pain neuroplasticity as targets for analgesic development. Curr Topics Med Chem 2005, 5:557-567.
60. Cook AJ, Woolf CJ, Wall PD, McMahon SB: Dynamic receptive field plasticity in rat spinal cord dorsal horn following C-primary afferent input. Nature 1987, 325:151-153.
61. Henriksson KG: Is fibromyalgia a distinct clinical entity? Pain mechanisms in fibromyalgia syndrome. A myologist's view. Best Pract Res Clin Rheumatol 1999, 13:455-461.
62. Bengtsson A, Henriksson KG, Larsson J: Muscle biopsy in primary fibromyalgia. Light-microscopical and histochemical findings. Scand J Rheumatol 1986, 15:1-6.
63. Bengtsson A, Henriksson KG, Jorfeldt L, Kagedal B, Lennmarken C, Lindstrom F: Primary fibromyalgia. A clinical and laboratory study of 55 patients. Scand J Rheumatol 1986, 15:340-347.
64. Pongratz DE, Spath M: Morphologic aspects of fibromyalgia. Z Rheumatol 1998, 57:47-51.
65. Bennett RM, Clark SR, Goldberg L, Nelson D, Bonafede RP, Porter J, Specht D: Aerobic fitness in patients with fibrositis. A controlled study of respiratory gas exchange and 133xenon clearance from exercising muscle. Arthritis Rheum 1989, 32: 454-460.
66. Lund N, Bengtsson A, Thorborg P: Muscle tissue oxygen pressure in primary fibromyalgia. Scan J Rheumatol 1986, 15:165-173.
67. de Kerviler E, Leroy-Willig A, Jehenson P, Duboc D, Eymard B, Syrota A: Exercise-induced muscle modifications: study of healthy subjects and patients with metabolic myopathies with MR imaging and P-31 spectroscopy. Radiology 1991, 181:259-264.
68. Sluka KA, Kalra A, Moore SA: Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve 2001, 24:37-46.
69. Park JH, Phothimat P, Oates CT, Hernanz-Schulman M, Olsen NJ: Use of P-31 magnetic resonance spectroscopy to detect metabolic abnormalities in muscles of patients with fibromyalgia. Arthritis Rheum 1998, 41:406-413.
70. Jubrias SA, Bennett RM, Klug GA: Increased incidence of a resonance in the phosphodiester region of 31P nuclear magnetic resonance spectra in the skeletal muscle of fibromyalgia patients. Arthritis Rheum 1994, 37:801-807.
71. Shah JP, Phillips TM, Danoff JV, Gerber LH: An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol 2005, 99:1977-1984.
72. Rosendal L, Kristiansen J, Gerdle B, Sogaard K, Peolsson M, Kjaer M, Sorensen J, Larsson B: Increased levels of interstitial potassium but normal levels of muscle IL-6 and LDH in patients with trapezius myalgia. Pain 2005, 119:201-209.
73. Ruster M, Franke S, Spath M, Pongratz DE, Stein G, Hein GE: Detection of elevated N-epsilon-carboxymethyllysine levels in muscular tissue and in serum of patients with fibromyalgia. Scand J Rheumatol 2005, 34:460-463.
74. Wall PD, Woolf CJ: Muscle but not cutaneous C-afferent input produces prolonged increases in the excitability of the flexion reflex in the rat. J Physiol Lond 1984, 356:443-458.
75. Price DD, Hu JW, Dubner R, Gracely RH: Peripheral suppression of first pain and central summation of second pain evoked by noxious heat pulses. Pain 1977, 3:57-68.